Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376111211> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4376111211 endingPage "E13" @default.
- W4376111211 startingPage "E13" @default.
- W4376111211 abstract "The advanced therapy product tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy that has brought hope for children and young adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We sought to evaluate the cost-effectiveness of tisagenlecleucel compared with conventional salvage therapies in pediatric and young adult patients with R/R B-ALL.This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses parameters as registered in International Prospective Register of Systematic Reviews (CRD42021266998). Literature was searched using the MEDLINE databases via PubMed, EMBASE, Lilacs, the Cochrane Central Register of Controlled Trials and Web of Science in January 2022. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts were reviewed.In total, 5627 publications were identified, from which six eligible studies were selected. The conventional therapies identified were blinatumomab (Blina), clofarabine monotherapy (Clo-M), clofarabine combined with cyclophosphamide and etoposide (Clo-C) and the combination of fludarabine, cytarabine and idarubicin (FLA-IDA). The discounted incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained for tisagenlecleucel compared with Clo-C and Blina averages was $38 837 and $25 569, respectively. In relation to the cost of the drug, the average of tisagenlecleucel was approximately 4.3 times, 10.8 times or 4.7 times greater than the Clo-M, Clo-C and Blina, respectively.This systematic review highlighted that tisagenlecleucel is a much more expensive therapy than conventional alternatives. However, tisagenlecleucel performed well on the ICER, not exceeding $100 000/QALY. It was also found that the advanced therapy product was more effective than the conventional small molecule and biological drugs, in terms of life years and QALY gained." @default.
- W4376111211 created "2023-05-12" @default.
- W4376111211 creator A5007294589 @default.
- W4376111211 creator A5017090306 @default.
- W4376111211 creator A5056446911 @default.
- W4376111211 creator A5065005217 @default.
- W4376111211 creator A5076005339 @default.
- W4376111211 creator A5076104674 @default.
- W4376111211 creator A5088498980 @default.
- W4376111211 creator A5091918368 @default.
- W4376111211 date "2023-05-01" @default.
- W4376111211 modified "2023-10-18" @default.
- W4376111211 title "Immunotherapy: PLATELETS INDUCE REGULATORY T-CELL EXPANSION DURING CAR-T CELL MANUFACTURING" @default.
- W4376111211 doi "https://doi.org/10.1016/s1465-3249(23)00722-3" @default.
- W4376111211 hasPublicationYear "2023" @default.
- W4376111211 type Work @default.
- W4376111211 citedByCount "0" @default.
- W4376111211 crossrefType "journal-article" @default.
- W4376111211 hasAuthorship W4376111211A5007294589 @default.
- W4376111211 hasAuthorship W4376111211A5017090306 @default.
- W4376111211 hasAuthorship W4376111211A5056446911 @default.
- W4376111211 hasAuthorship W4376111211A5065005217 @default.
- W4376111211 hasAuthorship W4376111211A5076005339 @default.
- W4376111211 hasAuthorship W4376111211A5076104674 @default.
- W4376111211 hasAuthorship W4376111211A5088498980 @default.
- W4376111211 hasAuthorship W4376111211A5091918368 @default.
- W4376111211 hasConcept C126322002 @default.
- W4376111211 hasConcept C143998085 @default.
- W4376111211 hasConcept C187212893 @default.
- W4376111211 hasConcept C2776694085 @default.
- W4376111211 hasConcept C2776755627 @default.
- W4376111211 hasConcept C2777198975 @default.
- W4376111211 hasConcept C2778020697 @default.
- W4376111211 hasConcept C2778041864 @default.
- W4376111211 hasConcept C2778461978 @default.
- W4376111211 hasConcept C2779263901 @default.
- W4376111211 hasConcept C2909962599 @default.
- W4376111211 hasConcept C71924100 @default.
- W4376111211 hasConceptScore W4376111211C126322002 @default.
- W4376111211 hasConceptScore W4376111211C143998085 @default.
- W4376111211 hasConceptScore W4376111211C187212893 @default.
- W4376111211 hasConceptScore W4376111211C2776694085 @default.
- W4376111211 hasConceptScore W4376111211C2776755627 @default.
- W4376111211 hasConceptScore W4376111211C2777198975 @default.
- W4376111211 hasConceptScore W4376111211C2778020697 @default.
- W4376111211 hasConceptScore W4376111211C2778041864 @default.
- W4376111211 hasConceptScore W4376111211C2778461978 @default.
- W4376111211 hasConceptScore W4376111211C2779263901 @default.
- W4376111211 hasConceptScore W4376111211C2909962599 @default.
- W4376111211 hasConceptScore W4376111211C71924100 @default.
- W4376111211 hasIssue "6" @default.
- W4376111211 hasLocation W43761112111 @default.
- W4376111211 hasOpenAccess W4376111211 @default.
- W4376111211 hasPrimaryLocation W43761112111 @default.
- W4376111211 hasRelatedWork W2019618063 @default.
- W4376111211 hasRelatedWork W2156392706 @default.
- W4376111211 hasRelatedWork W2227661629 @default.
- W4376111211 hasRelatedWork W2397265158 @default.
- W4376111211 hasRelatedWork W2522830609 @default.
- W4376111211 hasRelatedWork W2531219802 @default.
- W4376111211 hasRelatedWork W2738123701 @default.
- W4376111211 hasRelatedWork W2804171728 @default.
- W4376111211 hasRelatedWork W2890859706 @default.
- W4376111211 hasRelatedWork W4381245411 @default.
- W4376111211 hasVolume "25" @default.
- W4376111211 isParatext "false" @default.
- W4376111211 isRetracted "false" @default.
- W4376111211 workType "article" @default.